0000000000202125

AUTHOR

John Mancini

showing 2 related works from this author

Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.

2019

International audience; Recently, concerns regarding the safety of red yeast rice (RYR) have been raised after the publication of some case reports claiming toxicity. Since the previous meta-analyses on the effects of RYR were mainly focused on its efficacy to improve lipid profile and other cardiovascular parameters, we carried out a meta-analysis on safety data derived from the available randomized controlled clinical trials (RCTs). Primary outcomes were musculoskeletal disorders (MuD). Secondary outcomes were non-musculoskeletal adverse events (Non-MuD) and serious adverse events (SAE). Subgroups analyses were carried out considering the intervention (RYR alone or in association with oth…

0301 basic medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]PlaceboMusculoskeletal disorderslaw.invention03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemRandomized controlled triallawInternal medicineNon-musculoskeletal adverse eventmedicineRed yeast riceHumansMusculoskeletal DiseasesAdverse effectRandomized Controlled Trials as TopicPharmacologyBiological Productsbusiness.industryMusculoskeletal disorderOdds ratioNon-musculoskeletal adverse eventsSerious adverse events[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good health[SDV] Life Sciences [q-bio]Clinical trial030104 developmental biologyRed yeast riceTolerability030220 oncology & carcinogenesisMeta-analysisDietary SupplementsSafetybusinessPharmacological research
researchProduct

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

2023

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the dis…

PharmacologySettore MED/04 - Patologia GeneraleNAFLDLiver steatosisPosition paperDietary supplements; Liver steatosis; NAFLD; Nutraceuticals; Position paper;NutraceuticalsDietary supplements
researchProduct